Previous studies have shown that Mfn2 agonists could reverse mitochondrial defects in preclinical models of neurodegenerative disease of Charcot Marie Tooth disease type 2A (CMT2A) by mechanistically ameliorating mitochondrial trafficking33. This evidence concerns the gene MFN2 and Charcot-Marie-Tooth disease type 2A1.